Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
Grifols is a global healthcare company founded in Barcelona in 1909 committed to i...
Grifols is a global healthcare company founded ...
Kumba Health is an online platform connecting doctors with patients. Kumba Health ...
Kumba Health is an online platform connecting d...
Insulet Corporation is an innovative medical device company based in Acton, Massac...
Insulet Corporation is an innovative medical de...
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
Join the National Investor Network and get the latest information with your interests in mind.